AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27423645 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated local relapses in the posterior fossa (PF)
Number of subjects: 338
Study 27423645 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniospinal, metastatic relapses
Number of subjects: 338
Study 27423645 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration of new drugs
Number of subjects: 338
Study 23647413 — intervention group
Group type: EXPERIMENTAL
Intervention: Number changes
Number of subjects: 0
Study 23647413 — intervention group
Group type: COMPARATOR
Intervention: Cumulative area changes
Number of subjects: 0
Study 23559791 — intervention group
Group type: EXPERIMENTAL
Intervention: Guduchyadi Medhya Rasayana
Number of subjects: 138
Study 23559791 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 138
Study 20438395 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPI-test after pneumatic tube delivery
Number of subjects: 0
Study 20438395 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAP-test
Number of subjects: 0
Study 20438395 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalisation of the ASPI-test result using the TRAP-test result
Number of subjects: 0
Study 18457472 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene (10, 20 and 40 mg)
Number of subjects: 7492
Study 18457472 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene
Number of subjects: 7492
Study 18457472 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene (60 mg)
Number of subjects: 7492
Study 18457472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7492
Study 16995893 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month clinical intervention (4 contacts) to facilitate internalization of autonomy and perceived competence for tobacco abstinence and reduced percent calories from fat.
Number of subjects: 1006
Study 16995893 — intervention group
Group type: COMPARATOR
Intervention: Community care (control group).
Number of subjects: 1006
Study 12424044 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg morphine in 20 ml normal saline (Group B)
Number of subjects: 30
Study 12424044 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg morphine in 20 ml normal saline (Group C)
Number of subjects: 30
Study 12424044 — intervention group
Group type: COMPARATOR
Intervention: 20 ml normal saline (Group A)
Number of subjects: 30
Study 10433851 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open‐angle glaucoma (POAG)
Number of subjects: 75
Study 10433851 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (N)
Number of subjects: 75
Study 10433851 — intervention group
Group type: COMPARATOR
Intervention: Normal-pressure glaucoma (NPG)
Number of subjects: 75
Study 8585189 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 unit fresh whole blood (FWB)
Number of subjects: 24
Study 8585189 — intervention group
Group type: COMPARATOR
Intervention: 1 unit irradiated fresh whole blood (IrFWB, 1,500 cGy)
Number of subjects: 24
Study 2186991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol administered via the Autohaler
Number of subjects: 13
Study 2186991 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol administered via the Diskhaler
Number of subjects: 13
Study 6777263 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate
Number of subjects: 20
Study 6777263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31120601 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalated radiation therapy (<66 Gy)
Number of subjects: 1168
Study 31120601 — intervention group
Group type: COMPARATOR
Intervention: Full-dose radiation therapy (≥66 Gy)
Number of subjects: 1168
Study 29191811 — intervention group
Group type: EXPERIMENTAL
Intervention: Laerdal Upright Resuscitator with snap-fit mask
Number of subjects: 40
Study 29191811 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Laerdal infant resuscitator with snap-fit mask
Number of subjects: 40
Study 29191811 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Piece Resuscitator (Neopuff) with snap-fit mask
Number of subjects: 40
Study 29191811 — intervention group
Group type: COMPARATOR
Intervention: Standard Laerdal infant resuscitator with standard mask
Number of subjects: 40
Study 29191811 — intervention group
Group type: COMPARATOR
Intervention: T-Piece Resuscitator (Neopuff) with standard mask
Number of subjects: 40
Study 29191811 — intervention group
Group type: COMPARATOR
Intervention: Laerdal Upright Resuscitator with standard mask
Number of subjects: 40
Study 27241374 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior (DA) approach
Number of subjects: 0
Study 27241374 — intervention group
Group type: COMPARATOR
Intervention: Direct Lateral approach
Number of subjects: 0
Study 25409738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g by intravenous injection followed by 3 g intravenous infusion over 24 hours)
Number of subjects: 8000
Study 25409738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 8000
Study 22772170 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine (2-dose regimen at a 1-month interval)
Number of subjects: 3388
Study 20142523 — intervention group
Group type: EXPERIMENTAL
Intervention: Latrepirdine, 20 mg 3 times daily (n = 46)
Number of subjects: 91
Study 20142523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 45)
Number of subjects: 91
Study 17477888 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg/d (with dose adjustment to 50 mg/d if insufficient improvement)
Number of subjects: 238
Study 17477888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 15618254 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles with single embryo transfer (SET)
Number of subjects: 107
Study 15618254 — intervention group
Group type: COMPARATOR
Intervention: One cycle with double embryo transfer (DET)
Number of subjects: 107
Study 12137873 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/d)
Number of subjects: 0
Study 12137873 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (5 mg/d)
Number of subjects: 0
Study 9744696 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 73
Study 9744696 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 73
Study 9744696 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 73
Study 8039940 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 0
Study 8039940 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 0
Study 2722722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole
Number of subjects: 49
Study 2722722 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 49
Study 29424236 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (up to 10 sessions based on cognitive behavioural therapy) plus usual care
Number of subjects: 51
Study 29424236 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study 28822518 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR>0.8 and kept on medical follow-up
Number of subjects: 282
Study 28822518 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR≤0.8 and underwent revascularisation (PCI in 144 & CABG in 31)
Number of subjects: 282
Study 28822518 — intervention group
Group type: COMPARATOR
Intervention: FFR≤0.8 and refused to undergo revascularisation
Number of subjects: 282
Study 25521788 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer simulation program for personal protective equipment training (experimental group)
Number of subjects: 50
Study 25521788 — intervention group
Group type: COMPARATOR
Intervention: Conventional personal protective equipment training only (control group)
Number of subjects: 50
Study 22114787 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3‐fortified yogurt drink (FYD; containing 170 mg calcium and 500 IU/250 mL)
Number of subjects: 100
Study 22114787 — intervention group
Group type: COMPARATOR
Intervention: Plain yogurt drink (PYD; containing 170 mg calcium and no vitamin D/250 mL)
Number of subjects: 100
Study 22114787 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3‐fortified yogurt drink (FYD)
Number of subjects: 100
Study 22114787 — intervention group
Group type: COMPARATOR
Intervention: Plain yogurt drink (PYD)
Number of subjects: 100
Study 20225476 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.10 mm diameter cast Ni-Cr alloy post-core
Number of subjects: 32
Study 20225476 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.50 mm diameter cast Ni-Cr alloy post-core
Number of subjects: 32
Study 20225476 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.70 mm diameter cast Ni-Cr alloy post-core
Number of subjects: 32
Study 20225476 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.00 mm diameter cast Ni-Cr alloy post-core
Number of subjects: 32
Study 16464371 — intervention group
Group type: EXPERIMENTAL
Intervention: 'yi qi tiao xue, fu ben pei yuan' acupuncture method (supplementing vital force‐matter and regulating blood, supporting the root and fostering the source)
Number of subjects: 60
Study 16464371 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (medication and traditional acupuncture treatment)
Number of subjects: 60
Study 15175213 — intervention group
Group type: COMPARATOR
Intervention: Plain lubricant
Number of subjects: 100
Study 15175213 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine gel
Number of subjects: 100
Study 15175213 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger women (aged 18-59)
Number of subjects: 100
Study 15175213 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural pain
Number of subjects: 100
Study 11131819 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal evaluation of moves
Number of subjects: 0
Study 11131819 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-verbal evaluation of moves (key press)
Number of subjects: 0
Study 11131819 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation processes
Number of subjects: 0
Study 11131819 — intervention group
Group type: COMPARATOR
Intervention: Non-evaluated solutions
Number of subjects: 0
Study 9068022 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mmol/L lactate dialysate
Number of subjects: 47
Study 9068022 — intervention group
Group type: EXPERIMENTAL
Intervention: 38 mmol/L bicarbonate fluid
Number of subjects: 47
Study 9068022 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mmol/L bicarbonate and 15 mmol/L lactate dialysate
Number of subjects: 47
Study 7814812 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha interferon treatment
Number of subjects: 751
Study 7814812 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose alpha interferon (≤ 200 MU/m2)
Number of subjects: 751
Study 7814812 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium/high dose alpha interferon (≥ 200 MU/m2)
Number of subjects: 751
Study 7814812 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 751
Study 2690545 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin
Number of subjects: 145
Study 2690545 — intervention group
Group type: COMPARATOR
Intervention: 12 g cholestyramine
Number of subjects: 145
Study 1099036 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% sodium thiosulfate application
Number of subjects: 134
Study 1099036 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% sodium thiosulfate application plus ultraviolet light
Number of subjects: 134
Study 1099036 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% sodium thiosulfate application, ultraviolet light, and meladinine tablets (amoidin 0.01 g and amidin 0.005 g)
Number of subjects: 134
Study 31585966 — intervention group
Group type: EXPERIMENTAL
Intervention: New revised manual and a 1-day workshop delivered by voluntary sector service providers
Number of subjects: 64
Study 31585966 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 64
Study 26829647 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 or 60 mg gevokizumab every 4 weeks intravenously or subcutaneously
Number of subjects: 21
Study 26829647 — intervention group
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Number of subjects: 21
Study 24164634 — intervention group
Group type: EXPERIMENTAL
Intervention: Full vision
Number of subjects: 28
Study 24164634 — intervention group
Group type: COMPARATOR
Intervention: Target only vision
Number of subjects: 28
Study 22406015 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 40 m s(‐2) (30 Hz High, 2.5 mm)
Number of subjects: 14
Study 22406015 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with hand straps
Number of subjects: 14
Study 22406015 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with soft mat
Number of subjects: 14
Study 22406015 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no WBV)
Number of subjects: 14
Study 20713437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation therapy (CST)
Number of subjects: 32
Study 20713437 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 18589556 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin zeta (10,000 IU, subcutaneous injection)
Number of subjects: 48
Study 18589556 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa (10,000 IU, subcutaneous injection)
Number of subjects: 48
Study 16583597 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening lamp and peroxide gel (20% hydrogen peroxide)
Number of subjects: 50
Study 16583597 — intervention group
Group type: COMPARATOR
Intervention: No light treatment with peroxide gel (20% hydrogen peroxide)
Number of subjects: 50
Study 11854731 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous saphenous vein (ASV)
Number of subjects: 195
Study 11854731 — intervention group
Group type: COMPARATOR
Intervention: Synthetic patches
Number of subjects: 195
Study 10235191 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat meal (10% fat, 14% proteins, 76% carbohydrates)
Number of subjects: 12
Study 10235191 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal (50% fat, 18% proteins, 32% carbohydrates)
Number of subjects: 12
Study 7633717 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled indomethacin (3 mg/m2 body-surface area)
Number of subjects: 10
Study 7633717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 10
Study 7633717 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled indomethacin
Number of subjects: 10
Study 2653057 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine, 800 mg/day
Number of subjects: 66
Study 2653057 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam, 120 mg/day
Number of subjects: 66
Study 71396 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated measles vaccine (Schwarz strain)
Number of subjects: 5000
Study 71396 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated group
Number of subjects: 5000
Study 30201160 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech Recognition (SR) intervention
Number of subjects: 4510
Study 28673375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary inflammatory index (DII) score
Number of subjects: 1304
Study 28673375 — intervention group
Group type: EXPERIMENTAL
Intervention: High DII scores
Number of subjects: 1304
Study 26158868 — intervention group
Group type: COMPARATOR
Intervention: Standard-size ETT (8.0 mm for men and 7.5 mm for women)
Number of subjects: 49
Study 26158868 — intervention group
Group type: EXPERIMENTAL
Intervention: Small ETT (7.0 mm for men and 6.5 mm for women)
Number of subjects: 49
Study 24085380 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous compression plate (PCCP)
Number of subjects: 90
Study 24085380 — intervention group
Group type: COMPARATOR
Intervention: Proximal femoral nail anti-rotation (PFNA)
Number of subjects: 90
Study 21897262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternotomy (group TLV)
Number of subjects: 0
Study 21897262 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracotomy (group OLV)
Number of subjects: 0
Study 19117865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucinactant 90 mg/kg
Number of subjects: 136
Study 19117865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucinactant 175 mg/kg
Number of subjects: 136
Study 19117865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham air)
Number of subjects: 136
Study 16434916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail survey
Number of subjects: 9126
Study 16434916 — intervention group
Group type: COMPARATOR
Intervention: Web survey
Number of subjects: 9126
Study 16434916 — intervention group
Group type: COMPARATOR
Intervention: IVR survey
Number of subjects: 9126
Study 16434916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail and Web comparison
Number of subjects: 9126
Study 16434916 — intervention group
Group type: COMPARATOR
Intervention: IVR comparison
Number of subjects: 9126
Study 16434916 — intervention group
Group type: COMPARATOR
Intervention: Cost comparison
Number of subjects: 9126
Study 15017527 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARB)
Number of subjects: 0
Study 15017527 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ARB and ACE inhibition
Number of subjects: 0
Study 15017527 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB
Number of subjects: 0
Study 15017527 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan and Irbesartan (specific ARBs)
Number of subjects: 0
Study 11701102 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal tests of interaction
Number of subjects: 200
Study 11701102 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup-specific tests
Number of subjects: 200
Study 11701102 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal interaction tests
Number of subjects: 200
Study 11701102 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup-specific analyses
Number of subjects: 200
Study 11701102 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflation factor for sample size
Number of subjects: 200
Study 11701102 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses
Number of subjects: 200
Study 9233053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (SU) 6 mg s.c.
Number of subjects: 14
Study 9233053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study 9233053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (SU) plus GHRH
Number of subjects: 14
Study 9233053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) plus GHRH
Number of subjects: 14
Study 9233053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (SU)
Number of subjects: 14
Study 8365194 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical models (Altham's and beta-binomial) for analyzing graft occlusion rates
Number of subjects: 349
Study 8365194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed model or Markov-like susceptibility model
Number of subjects: 349
Study 2877129 — intervention group
Group type: EXPERIMENTAL
Intervention: Synvinolin (MK-733) 2.5 mg/day
Number of subjects: 43
Study 2877129 — intervention group
Group type: EXPERIMENTAL
Intervention: Synvinolin (MK-733) 80 mg/day
Number of subjects: 43
Study 2877129 — intervention group
Group type: EXPERIMENTAL
Intervention: Synvinolin (MK-733) (doses ranging from 2.5 mg to 80 mg per day)
Number of subjects: 43
Study 2877129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 29103133 — intervention group
Group type: EXPERIMENTAL
Intervention: Growtropin®‐II (recombinant human GH)
Number of subjects: 70
Study 29103133 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 27786541 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min cold-water immersion at 8 °C
Number of subjects: 15
Study 27786541 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min cold-water immersion at 8 °C
Number of subjects: 15
Study 27786541 — intervention group
Group type: COMPARATOR
Intervention: Passive rest
Number of subjects: 15
Study 25472660 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioembolisation (RE) with yttrium-90 microspheres (SIR-Spheres™)
Number of subjects: 440
Study 25472660 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 440
Study 22831889 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil during cardiac surgery
Number of subjects: 120
Study 22831889 — intervention group
Group type: COMPARATOR
Intervention: Not receiving remifentanil
Number of subjects: 120
Study 20059676 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient feedback training programme in addition to regular communication skills training
Number of subjects: 53
Study 20059676 — intervention group
Group type: COMPARATOR
Intervention: Regular communication skills training
Number of subjects: 53
Study 18226766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 19
Study 18226766 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (intravenous diuretics)
Number of subjects: 19
Study 15629205 — intervention group
Group type: EXPERIMENTAL
Intervention: Huntington's disease patients
Number of subjects: 22
Study 15629205 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 22
Study 12589153 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (1600 mg/day in two divided doses)
Number of subjects: 64
Study 12589153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10779192 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure (vacuum suction) at 40 mmHg
Number of subjects: 24
Study 10779192 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure (vacuum suction) at 50 mmHg
Number of subjects: 24
Study 10779192 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure (vacuum suction) at 60 mmHg
Number of subjects: 24
Study 10779192 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure (vacuum suction) at 70 mmHg
Number of subjects: 24
Study 10779192 — intervention group
Group type: COMPARATOR
Intervention: Control (no vacuum)
Number of subjects: 24